A5072452238- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Radiomics and Machine Learning in Medical Imaging
- Cancer Genomics and Diagnostics
- Cancer therapeutics and mechanisms
- Gastric Cancer Management and Outcomes
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Occupational and environmental lung diseases
- Cancer Treatment and Pharmacology
- RNA modifications and cancer
- Pleural and Pulmonary Diseases
- Medical Imaging Techniques and Applications
- Acute Lymphoblastic Leukemia research
- Pancreatic and Hepatic Oncology Research
- Neuroendocrine Tumor Research Advances
- Multiple and Secondary Primary Cancers
- Brain Metastases and Treatment
- Lymphoma Diagnosis and Treatment
- Intraperitoneal and Appendiceal Malignancies
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Cancer Immunotherapy and Biomarkers
- Bladder and Urothelial Cancer Treatments
- Colorectal and Anal Carcinomas
Eli Lilly (United States)
2007-2025
Eli Lilly (Netherlands)
2015-2024
Princess Margaret Cancer Centre
2000-2023
Aarhus University Hospital
2000-2023
Lilly (China)
2021
University Medical Center Hamburg-Eppendorf
2009-2013
Heidelberg University
2007-2013
University Hospital Heidelberg
2007-2013
Universität Hamburg
2009-2013
University of Turin
2011
PURPOSE: Gemcitabine plus cisplatin (GC) and methotrexate, vinblastine, doxorubicin, (MVAC) were compared in patients with locally advanced or metastatic transitional-cell carcinoma (TCC) of the urothelium. PATIENTS AND METHODS: Patients stage IV TCC no prior systemic chemotherapy randomized to GC (gemcitabine 1,000 mg/m 2 days 1, 8, 15; 70 day 2) standard MVAC every 28 for a maximum six cycles. RESULTS: Four hundred five (GC, n = 203; MVAC, 202). The groups well-balanced respect prognostic...
Purpose In the phase III PARAMOUNT trial, pemetrexed continuation maintenance therapy reduced risk of disease progression versus placebo (hazard ratio [HR], 0.62; 95% CI, 0.49 to 0.79; P < .001). Here we report final overall survival (OS) and updated safety data. Patients Methods all, 939 patients with advanced nonsquamous non–small-cell lung cancer (NSCLC) received four cycles pemetrexed-cisplatin induction therapy; then, 539 no Eastern Cooperative Oncology Group performance status 0 or...
This study aimed to determine whether three preoperative cycles of gemcitabine plus cisplatin followed by radical surgery provides a reduction in the risk progression compared with alone patients stages IB IIIA non-small-cell lung cancer (NSCLC).Patients chemotherapy-naive NSCLC (stages IB, II, or IIIA) were randomly assigned receive either 1,250 mg/m(2) days 1 and 8 every 3 weeks 75 day surgery, alone. Randomization was stratified center disease stage (IB/IIA v IIB/IIIA). The primary end...
Purpose Following a phase II trial in which pemetrexed-platinum demonstrated similar activity to that of historical etoposide-platinum controls, III study was conducted compare pemetrexed-carboplatin with etoposide-carboplatin for the treatment extensive-stage small-cell lung cancer (ES-SCLC). Patients and Methods Chemotherapy-naive patients ES-SCLC an Eastern Cooperative Oncology Group performance status zero 2 were randomly assigned receive (pemetrexed 500 mg/m on day 1; carboplatin at...
Gemcitabine plus cisplatin (GC) and methotrexate, vinblastine, doxorubicin, (MVAC) were compared in patients with locally advanced or metastatic transitional-cell carcinoma (TCC) of the urothelium.
In retrospective analyses of patients with nonsquamous non-small-cell lung cancer treated pemetrexed, low thymidylate synthase (TS) expression is associated better clinical outcomes. This phase II study explored this association prospectively at the protein and mRNA-expression level.Treatment-naive (stage IIIB/IV) had four cycles first-line chemotherapy pemetrexed/cisplatin. Nonprogressing continued on pemetrexed maintenance until progression or maximum tolerability. TS...
Abstract Purpose: In EGFR-mutated metastatic non–small cell lung cancer (NSCLC), outcomes from EGFR tyrosine kinase inhibitors have differed historically by mutation type present, with lower benefit reported in patients ex21L858R versus ex19del mutations. We investigated if EGFR-activating subtypes impact treatment the phase III RELAY study. Associations between and preexisting co-occurring treatment-emergent genetic alterations were also explored. Patients Methods: NSCLC, an or mutation, no...
To determine the toxicity, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of oral gemcitabine (2',2'-difluorodeoxycytidine; dFdC) in patients with cancer.Patients advanced or metastatic cancer refractory to standard therapy were eligible. Gemcitabine was administered p.o. starting at 1 mg once daily using dose escalation three per level. Patients received one two dosing schemes: (a) for 14 days a 21-day cycle (b) every other day 21 28-day cycle....
LBA7507 The full, final text of this abstract will be available at abstract.asco.org 12:01 AM (EDT) on Monday, June 4, 2012, and in the Annual Meeting Proceedings online supplement to 20, issue Journal Clinical Oncology. Onsite Meeting, printed Monday edition ASCO Daily News.
Ramucirumab plus erlotinib (RAM + ERL) demonstrated superior progression-free survival (PFS) over placebo ERL (PBO in the phase III RELAY study of patients with epidermal growth factor receptor (EGFR)-mutated metastatic non-small-cell lung cancer (EGFR+ mNSCLC; NCT02411448). Next-generation sequencing (NGS) was used to identify clinically relevant alterations circulating tumor DNA (ctDNA) and explore their impact on treatment outcomes.Eligible EGFR+ mNSCLC were randomized 1 : (150 mg/day)...